News

The Pennsylvania based global pharma rolled out Methylphenidate Hydrochloride extended-release tablets USP, 18mg, 27mg, 36mg and 54mg, which are indicted for treatment of Attention Deficit Hyperactivity Disorder (ADHD).

The brands bought by Zydus Healthcare in the deal are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten which are expected to strengthen the global pharmaceutical group’s portfolio in

Effi-7, an antagonist of the interleukin-7 receptor, is intended to treat patients suffering from invalidating autoimmune pathologies. The deal is inclusive of an upfront payment of €10.25m by

Kubota Pharmaceutical will hold 51% stake while the remainder will be held by SBI in the unnamed joint venture which will organize and manage special purpose entities in

As part of the deal, Pfizer has acquired the commercialisation and development rights of AstraZeneca’s approved antibiotics Merrem, Zinforo and Zavicefta as well as its ATM-AVI and CXL

Under the collaboration, Ionis and Janssen will continue to evaluate the target with the goal of advancing an antisense drug into development. Ionis chief operating officer B. Lynne

Metreleptin was granted orphan drug designation by the European Commission in July 2012, and if approved, carries 10 years of exclusivity in the EU. The company estimates the

The primary endpoint of incidence of DGF with a two-dose regimen of eculizumab compared with placebo did not reach statistical significance. DGF is an early and serious complication

Patients receiving emicizumab showed a statistically significant reduction in bleeds over time compared with those not being treated with it. The treatment also met secondary goals of reducing